Two Biotechs Get Beaten Down: Jaguar Health Collapses 59%, Viking Therapeutics Sinks 4%
Jaguar Health and Viking Therapeutics are both sinking Wednesday morning, but the forces behind each drop point in completely different directions, and the broader biotech sector is barely flinching.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Two biotechnology names are lower in Wednesday morning trading for unrelated reasons, and the biotechnology sector itself isn’t selling off. Jaguar Health (NASDAQ:JAGX) stock is at $14.21, down 59%, while Viking Therapeutics (NASDAQ:VKTX | VKTX Price Prediction) stock is at $39.11, down 4%.
The iShares Biotechnology ETF (NASDAQ:IBB) is down 0.1% in Wednesday morning trading, close to unchanged. Meanwhile, the SPDR S&P 500 ETF Trust (NYSEARCA:SPY) is down 0.44%, so the broad market is off by a wider margin than the biotechnology fund. Thus, two individual names are falling inside a sector that has barely moved.
What Is Behind Each Move
Jaguar Health is a small pharmaceutical company that develops prescription drugs derived from plants for gastrointestinal disease states. No company disclosure has been verified for Wednesday’s session, which leaves profit taking after a large prior run as the mechanism the figures support. That reading is offered as the likeliest explanation for the decline rather than as a confirmed cause, and Jaguar Health stock is still up 9% over the past month even after this session’s fall.
Viking Therapeutics is a different situation. The company reported positive top-line data from a maintenance trial of its obesity drug candidate and scheduled a special call to discuss the findings with investors. Its stock advanced sharply on Tuesday before giving part of that back on Wednesday, so this morning’s slip is a pullback that follows good news.
The Viking Therapeutics catalyst adds useful color. Positive top-line data from a maintenance trial is the kind of news that supports a longer investment thesis, and the company’s decision to schedule a special call for investors signals that management wanted the results framed in detail. That framing typically carries more weight over weeks than in the single session that follows.
The pattern in both stocks is worth naming clearly. A one-day drop that leaves a name higher on the month reads as a giveback, and both Jaguar Health and Viking Therapeutics fit that description on Wednesday. The nuance is that Jaguar Health’s giveback follows a very sharp run in a micro-cap where large percentage moves in either direction are routine.
Interpreting the Move Against the Sector
The IBB biotechnology fund is close to unchanged and the SPY broad-market fund is lower by more than it, which is the point of the framing. Jaguar Health and Viking Therapeutics are moving because of what is happening at each company on its own, and today’s session doesn’t offer a sector story to attach either decline to.
Viking Therapeutics stock is up 14% over the past month, so today’s decline sits inside a stretch of gains. Jaguar Health tells the more dramatic version of the same shape, with the stock still positive over the past month after a session that has taken it down by well over half. In both cases the one-month picture matters more than the one-day picture for judging where these names stand.
What to Watch Next
Investors can watch for whether Viking Therapeutics stock stabilizes once the maintenance data has been fully digested and whether the special investor call adds detail that shifts the read. The trial data is the operative news for Viking Therapeutics, and today’s slip doesn’t change that.
Jaguar Health stock is the trickier one to consider, because no verified disclosure sits behind Wednesday’s move. Traders may want to keep an eye on whether Jaguar Health finds a floor near current levels or continues to unwind the recent run. Readers weighing either name can calibrate their positions to the volatility on display, especially in a low-priced micro-cap where daily percentage swings are large.
The bigger picture across the biotechnology sector matters. too. With the IBB sector fund close to unchanged, there’s no shared trigger to look for, so traders can treat these two moves as company-specific rather than as evidence of anything broader. That framing sets expectations for how much either stock is likely to snap back or extend the move from here.
Contact [email protected] for any questions or corrections.
David Moadel is financial writer specializing in stocks, ETFs, options, precious metals, and Bitcoin. David has written well over 1,000 articles for leading online publications, helping investors understand markets, income strategies, and risk.His work has appeared in The Motley Fool, InvestorPlace, U.S. News & World Report, TipRanks, ValueWalk, Benzinga, Market Realist, TalkMarkets, Finmasters, 24/7 Wall St., and others.With a master’s degree in education, David has taught at the elementary, high school, and college levels. That teaching background shapes his writing style: clear, educational, and practical. David has also built a loyal social-media audience by providing trustworthy financial content on YouTube, X/Twitter, and StockTwits.
